Want to see IN:INDSWFTLAB full AI Analyst Report?
Top Page
Ind-Swift Laboratories Ltd.
(INDSWFTLAB)
Select Model
Select Model
Rating:51Neutral
Price Target:
₹402.00
▲(77.09% Upside)
Action:Reiterated
Date:08/27/26
The score is held back primarily by deteriorating cash flow (multi-year negative operating and free cash flow) and recent revenue contraction/earnings volatility. These risks are only partly offset by a meaningfully improved balance sheet and a strong upward technical trend, while the high P/E valuation limits upside confidence.
Positive Factors
Improved Balance Sheet
Lower leverage and a steadily expanding equity base improve the company’s ability to absorb operating volatility and finance required pharmaceutical activity. This strengthens balance-sheet resilience and may preserve strategic flexibility, although the sharp historical shifts warrant monitoring.
Negative Factors
Persistent Cash Burn
Negative operating cash flow in 2024–2026 and negative free cash flow in each of the last three years indicate that reported earnings are not converting into liquidity. Continued cash burn can constrain reinvestment, debt reduction, and resilience through weaker trading.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved Balance Sheet
Lower leverage and a steadily expanding equity base improve the company’s ability to absorb operating volatility and finance required pharmaceutical activity. This strengthens balance-sheet resilience and may preserve strategic flexibility, although the sharp historical shifts warrant monitoring.
Read all positive factors
Ind-Swift Laboratories Ltd. (INDSWFTLAB) vs. iShares MSCI India ETF (INDA)
Market Cap
₹30.65B
Dividend Yield1.14%
Average Volume (3M)46.79K
Price to Earnings (P/E)50.2
Beta (1Y)0.79
Revenue Growth113.34%
EPS Growth-80.12%
CountryIN
Employees1,388
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)6.82
Shares Outstanding86,961,555
10 Day Avg. Volume26,356
30 Day Avg. Volume46,786
Financial Highlights & Ratios
PEG Ratio-0.31
Price to Book (P/B)0.79
Price to Sales (P/S)1.71
P/FCF Ratio-10.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Ind-Swift Laboratories Ltd. Business Overview & Revenue Model
Company Description
Ind-Swift Laboratories Limited, an Indian enterprise, is engaged in the development, production, and distribution of active pharmaceutical ingredients (APIs). The company's comprehensive API portfolio addresses numerous therapeutic domains, includ...
How the Company Makes Money
The company primarily makes money by producing and selling active pharmaceutical ingredients (APIs) and pharmaceutical intermediates to other pharmaceutical companies that use these inputs to manufacture finished formulations (tablets, capsules, i...
Ind-Swift Laboratories Ltd. Financial Statement Overview
Summary
Income Statement
52
Neutral
Balance Sheet
72
Positive
Cash Flow
33
Negative
| Breakdown | TTM | Mar 2026 | Jun 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.65B | 6.41B | 5.62B | 12.81B | 12.07B | 10.39B |
| Gross Profit | 2.44B | 1.90B | 2.74B | 4.13B | 4.40B | 4.10B |
| EBITDA | 772.79M | 450.97M | 2.85B | 7.82B | 2.36B | 2.35B |
| Net Income | 573.25M | 414.15M | 2.50B | 4.21B | 475.97M | -21.49M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 16.73B | 14.38B | 14.60B | 18.24B | 18.01B |
| Cash, Cash Equivalents and Short-Term Investments | 4.42B | 4.72B | 4.82B | 4.94B | 231.54M | 333.68M |
| Total Debt | 0.00 | 205.01M | 408.41M | 166.22M | 8.62B | 9.53B |
| Total Liabilities | -13.84B | 2.89B | 2.65B | 6.48B | 11.42B | 12.00B |
| Stockholders Equity | 13.84B | 13.84B | 11.73B | 9.36B | 6.82B | 6.01B |
Cash Flow | ||||||
| Free Cash Flow | -472.94M | -1.08B | -898.80M | -2.08B | 1.82B | 1.32B |
| Operating Cash Flow | -202.50M | -198.64M | -254.74M | -1.63B | 1.95B | 1.50B |
| Investing Cash Flow | -1.04B | -1.28B | -1.10B | -1.23B | -133.68M | 47.72M |
| Financing Cash Flow | 961.18M | 1.47B | 692.05M | 6.99B | -1.86B | -1.41B |
Ind-Swift Laboratories Ltd. Technical Analysis
Neutral
227.00
Price Trends
363.07
Negative
283.90
Positive
206.70
Positive
Market Momentum
-4.41
Positive
41.02
Neutral
15.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:INDSWFTLAB, the sentiment is Neutral. The current price of 227 is below the 20-day moving average (MA) of 378.42, below the 50-day MA of 363.07, and above the 200-day MA of 206.70, indicating a neutral trend. The MACD of -4.41 indicates Positive momentum. The RSI at 41.02 is Neutral, neither overbought nor oversold. The STOCH value of 15.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:INDSWFTLAB.
Ind-Swift Laboratories Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | ₹10.67B | 10.68 | ― | 0.35% | 10.20% | 11.70% | |
74 Outperform | ₹21.28B | 17.42 | ― | 0.66% | 20.87% | 116.29% | |
56 Neutral | ₹26.02B | -76.92 | ― | 0.28% | -5.37% | -153.40% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | ₹30.65B | 50.22 | ― | 1.14% | 113.34% | -80.12% | |
51 Neutral | ₹31.12B | 83.97 | ― | 0.45% | 27.30% | 456.80% | |
47 Neutral | ₹21.54B | 798.28 | ― | 0.09% | 12.08% | ― |
* General Sector Average
IN:INDSWFTLAB
Ind-Swift Laboratories Ltd.
346.20
243.60
237.43%
IN:HIKAL
Hikal Limited
202.85
-40.71
-16.72%
IN:INDOCO
Indoco Remedies Limited
225.50
-56.75
-20.11%
IN:LINCOLN
Lincoln Pharmaceuticals Ltd
512.00
-12.11
-2.31%
IN:SOLARA
Solara Active Pharma Sciences Ltd.
618.65
24.50
4.12%
IN:VENUSREM
Venus Remedies Limited
1,439.15
991.83
221.73%
Ind-Swift Laboratories Ltd. Corporate Events
Ind-Swift Laboratories schedules virtual investor meet with Arihant Capital
Sep 23, 2026
Ind-Swift Laboratories Ltd. has scheduled a virtual group meeting with Arihant Capital on September 29, 2026, as part of its ongoing engagement with analysts and institutional investors under SEBI’s listing obligations framework. The company...
Ind-Swift Laboratories Publishes Notices for 31st AGM and Annual Report Access
Sep 6, 2026
Ind-Swift Laboratories Ltd., a listed Indian pharmaceutical company, manufactures and markets healthcare and drug products for a range of domestic and international customers. The company’s shares trade on BSE and NSE, positioning it within ...
Ind-Swift Laboratories Sets Q1 FY27 Earnings Call for August 17
Aug 12, 2026
Ind-Swift Laboratories Ltd. has scheduled an earnings conference call to discuss its financial results for the quarter ended June 30, 2026. The call will be held on Monday, August 17, 2026, at 3:00 p.m. IST and will feature senior finance and corp...
Ind-Swift Labs Revises EGM Notice on Preferential Issue for Expansion
Jul 29, 2026
Ind-Swift Laboratories Ltd. has issued a corrigendum to its July 10, 2026 notice convening an Extraordinary General Meeting on August 5, 2026, to update shareholders on changes to Item 1 regarding a proposed preferential issue. The EGM will be hel...
Ind-Swift Laboratories to Hold Extraordinary General Meeting via Video Conference on August 5
Jul 13, 2026
Ind-Swift Laboratories Ltd. has informed shareholders that it will hold its Extraordinary General Meeting on August 5, 2026, at 11:30 a.m. IST via video conferencing and other audio-visual means, with no physical venue. The company has published t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.